Natural history of Type 1 spinal muscular atrophy: a retrospective, global, multicenter study

Table 4 Sitting ability and head control assessed by HINE-2: ANCHOVY and FIREFISH Part 2

HINE-2 motor milestone	All ANCHOVY patients 18 months of age (N = 60)	All FIREFISH Part 2 patients 12 months of risdiplam treatment (N = 41)
Sitting, n (%)
Stable sit or pivots (rotates)	0	10 (24)
Sits with support at hips or props	0	15 (37)
Cannot sit	5 (8)	13 (32)
Not recorded in chart*	0	0
Head control, n (%)
All the time upright	0	18 (44)
Wobbles	0	13 (32)
Unable to maintain upright	5 (8)	7 (17)
Not recorded in chart*	0	0
Missing^†,‡	27 (45)	0
Censored^†,§	2 (3)	0
Death^†,¶	26 (43)	3 (7)

Able to sit is defined as achieving level 3 or 4 of HINE-2
*Hospital record exists at this time, but no mention of this motor milestone
^†Applies to both sitting and head control data
^‡No records for this time period
^§Patient was excluded from study at time points after starting treatment (nusinersen) or after enrollment in a clinical trial
^¶Patient died before the beginning of this time period
HINE-2, Hammersmith Infant Neurological Examination, Section 2

ISSN: 1750-1172